Terms: = Liver cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Treatment
88 results:
1. Comprehensive Analysis of the Immunosuppressive Function of Regulatory T Cells in Human Hepatocellular Carcinoma Tissues.
Ge J; Chen J; Shen Q; Zheng X; Chen X; Shi L; Chen L; Xu B
Cancer Control; 2024; 31():10732748241251580. PubMed ID: 38712609
[TBL] [Abstract] [Full Text] [Related]
2. Exploiting the immune system in hepatic tumor targeting: Unleashing the potential of drugs, natural products, and nanoparticles.
Hsu CY; Mustafa MA; Kumar A; Pramanik A; Sharma R; Mohammed F; Jawad IA; Mohammed IJ; Alshahrani MY; Ali Khalil NAM; Shnishil AT; Abosaoda MK
Pathol Res Pract; 2024 Apr; 256():155266. PubMed ID: 38554489
[TBL] [Abstract] [Full Text] [Related]
3. Multiple Immunomodulatory Strategies Based on Targeted Regulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Immune Homeostasis against Hepatocellular Carcinoma.
Fang S; Zheng L; Shu GF; Xiaoxiao C; Guo X; Ding Y; Yang W; Chen J; Zhao Z; Tu J; Chen M; Ji JS
ACS Nano; 2024 Mar; 18(12):8811-8826. PubMed ID: 38466366
[TBL] [Abstract] [Full Text] [Related]
4. The 'Other' subfamily of HECT E3 ubiquitin ligases evaluate the tumour immune microenvironment and prognosis in patients with hepatocellular carcinoma.
Dong R; Wang Z; Cao D; Li Y; Fei Y; Gao P; Zhu M; Chen Z; Cai J; Zuo X
IET Syst Biol; 2024 Feb; 18(1):23-39. PubMed ID: 38318939
[TBL] [Abstract] [Full Text] [Related]
5. FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer.
Li H; Zheng N; Guo A; Tang W; Li M; Cao Y; Ma X; Cao H; Ma Y; Wang H; Zhao S
Cell Death Dis; 2024 Feb; 15(2):107. PubMed ID: 38302412
[TBL] [Abstract] [Full Text] [Related]
6. Caffeine-folic acid-loaded-chitosan nanoparticles combined with methotrexate as a novel HepG2 immunotherapy targeting adenosine A2A receptor downstream cascade.
Hamed A; Ghareeb D; Mohamed TM; Hamed M; Nofal MS; Gaber M
BMC Complement Med Ther; 2023 Oct; 23(1):384. PubMed ID: 37891562
[TBL] [Abstract] [Full Text] [Related]
7. Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.
Suzuki H; Iwamoto H; Tanaka T; Sakaue T; Imamura Y; Masuda A; Nakamura T; Koga H; Hoshida Y; Kawaguchi T
Hepatol Int; 2024 Apr; 18(2):610-622. PubMed ID: 37864726
[TBL] [Abstract] [Full Text] [Related]
8. HBx promotes hepatocellular carcinoma progression by repressing the transcription level of miR-187-5p.
Deng Y; Wang L; Zhang Y; Sun D; Min H; Zhou H; Xu C; Xu N; Qiu F; Zhou J; Zhou J
Aging (Albany NY); 2023 Aug; 15(15):7533-7550. PubMed ID: 37531206
[TBL] [Abstract] [Full Text] [Related]
9. Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma.
Liang X; Gao H; Xiao J; Han S; He J; Yuan R; Yang S; Yao C
Front Immunol; 2023; 14():1185985. PubMed ID: 37334368
[TBL] [Abstract] [Full Text] [Related]
10. Muscarinic Acetylcholine Receptor M3 Expression and Survival in Human Colorectal Carcinoma-An Unexpected Correlation to Guide Future treatment?
Lobbes LA; Schütze MA; Droeser R; Arndt M; Pozios I; Lauscher JC; Hering NA; Weixler B
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175905
[TBL] [Abstract] [Full Text] [Related]
11. Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma.
Yan K; Zhang D; Chen Y; Lu W; Huang M; Cai J; Chen S; Bei T; Bai Y; Lv J; Fu Y; Zhang H
Front Immunol; 2023; 14():1116057. PubMed ID: 37056769
[TBL] [Abstract] [Full Text] [Related]
12. Depletion of Mannose Receptor-Positive Tumor-associated Macrophages via a Peptide-targeted Star-shaped Polyglutamate Inhibits Breast cancer Progression in Mice.
Lepland A; Malfanti A; Haljasorg U; Asciutto EK; Pickholz M; Bringas M; Đorđević S; Salumäe L; Peterson P; Teesalu T; Vicent MJ; Scodeller P
Cancer Res Commun; 2022 Jun; 2(6):533-551. PubMed ID: 36923553
[TBL] [Abstract] [Full Text] [Related]
13. TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments.
Liao P; Jiang M; Islam MS; Wang Y; Chen X
Front Immunol; 2023; 14():1097090. PubMed ID: 36865537
[TBL] [Abstract] [Full Text] [Related]
14. foxp3 and SQSTM1/P62 correlate with prognosis and immune infiltration in hepatocellular carcinoma.
Liu S; Zhang H; Yan J; Zhu J; Bai Z; Li X
Pathol Res Pract; 2023 Feb; 242():154292. PubMed ID: 36630868
[TBL] [Abstract] [Full Text] [Related]
15. GITR Ligation Improves Anti-PD1-Mediated Restoration of Human MMR-Proficient Colorectal Carcinoma Tumor-Derived T Cells.
Rakké YS; Campos Carrascosa L; van Beek AA; de Ruiter V; van Gemerden RS; Doukas M; Doornebosch PG; Vermaas M; Ter Borg S; van der Harst E; Coene PPLO; Kliffen M; Grünhagen DJ; Verhoef C; IJzermans JNM; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2023; 15(1):77-97. PubMed ID: 36155259
[TBL] [Abstract] [Full Text] [Related]
16. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study.
Simonelli M; Garralda E; Eskens F; Gil-Martin M; Yen CJ; Obermannova R; Chao Y; Lonardi S; Melichar B; Moreno V; Yu ML; Bongiovanni A; Calvo E; Rottey S; Machiels JP; Gonzalez-Martin A; Paz-Ares L; Chang CL; Mason W; Lin CC; Reardon DA; Vieito M; Santoro A; Meng R; Abbadessa G; Menas F; Lee H; Liu Q; Combeau C; Ternes N; Ziti-Ljajic S; Massard C
ESMO Open; 2022 Oct; 7(5):100562. PubMed ID: 35987165
[TBL] [Abstract] [Full Text] [Related]
17. Immune Evasion and Drug Resistance Mediated by USP22 in cancer: Novel Targets and Mechanisms.
Guo J; Zhao J; Fu W; Xu Q; Huang D
Front Immunol; 2022; 13():918314. PubMed ID: 35935969
[TBL] [Abstract] [Full Text] [Related]
18. Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Baldini C; Danlos FX; Varga A; Texier M; Halse H; Mouraud S; Cassard L; Champiat S; Signolle N; Vuagnat P; Martin-Romano P; Michot JM; Bahleda R; Gazzah A; Boselli L; Bredel D; Grivel J; Mohamed-Djalim C; Escriou G; Grynszpan L; Bigorgne A; Rafie S; Abbassi A; Ribrag V; Postel-Vinay S; Hollebecque A; Susini S; Farhane S; Lacroix L; Parpaleix A; Laghouati S; Zitvogel L; Adam J; Chaput N; Soria JC; Massard C; Marabelle A
J Exp Clin Cancer Res; 2022 Jul; 41(1):217. PubMed ID: 35794623
[TBL] [Abstract] [Full Text] [Related]
19. Metformin modulate immune fitness in hepatocellular carcinoma: Molecular and cellular approach.
Abd El-Fattah EE; Zakaria AY
Int Immunopharmacol; 2022 Aug; 109():108889. PubMed ID: 35679661
[TBL] [Abstract] [Full Text] [Related]
20. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract] [Full Text] [Related]
[Next]
